Annovis Bio, Inc. Stock News
$6.65
-0.640 (-8.78%)
At Close: May 28, 2024
We're Not Very Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Rate
11:22am, Tuesday, 28'th Jul 2020
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Stocks To Watch: Big Focus On Big Tech
08:26am, Saturday, 25'th Jul 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Annovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania
10:45am, Monday, 20'th Jul 2020
BERWYN, Pa., July 20, 2020 -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and.
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, reported that it
Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study
10:45am, Tuesday, 16'th Jun 2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced
Annovis Bio to Present at the June 2020 Virtual Summer Investor Summit
10:45am, Tuesday, 09'th Jun 2020
BERWYN, Pa., June 09, 2020 -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and.
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th
01:00pm, Wednesday, 03'rd Jun 2020
NEW YORK, NY / ACCESSWIRE / June 3, 2020 / The Virtual Summer Summit will take place on June 9 th -12 th , connecting 47 presenting small and microcap companies with distinguished investors from aroun
Annovis Bio Issued European Patent for Method of Treating Alzheimer’s Disease with ANVS401
10:45am, Tuesday, 02'nd Jun 2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced
Annovis Bio 2020 Annual Meeting of Stockholders to Be Held on June 3, 2020
10:45am, Monday, 01'st Jun 2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, will hold its 202
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced today
Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
10:00am, Friday, 01'st May 2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced today an intervi
Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson’s and Alzheimer’s Patients
10:45am, Thursday, 30'th Apr 2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced today
How Much Are Annovis Bio, Inc. (NYSEMKT:ANVS) Insiders Spending On Buying Shares?
10:09am, Wednesday, 29'th Apr 2020
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Annovis Bio Publishes Results of Alzheimer’s and Parkinson’s Animal Studies
11:00am, Thursday, 23'rd Apr 2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, published data from its two
Annovis Bio to Hold Investor Webinar and Q&A Session with CEO on April 14
09:30pm, Monday, 13'th Apr 2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced today its CEO Ma
